| Date | Title | Description |
| 26.03.2026 | Denteric Announces FDA IND Clearance for GPV381, a First-in-Class Therapeutic Vaccine Targeting Gingipain-Driven Inflammation in Periodontitis | Melbourne, Australia – Denteric today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for GPV381, a first-in-class therapeutic vaccine targeting gingipain toxins, key ups... |
| 17.03.2026 | Improving laboratory management and patient outcomes – Q-Sera announces first product launch of its RAPClotTM rapid serum blood collection tube technology in Japan | Melbourne, Australia – February 16, 2026
Q-Sera Pty Ltd, an Australian venture-backed company, today announced that leading Japanese medical device company, Terumo Corporation has launched VenoJect II RAPClotTM evacuated blood collection tu... |
| 20.01.2026 | Where Is the White Space in Drug Development? | Jonathan Tobin Partner at Brandon Capital
At Brandon Capital we spend most of our time creating and building companies discovering and developing new medicines that have the potential to deliver transformational benefit in important disease... |
| 03.11.2025 | The Billion-Dollar Biology of Oncology: What Really Drives Pharma’s Appetite? | By Jonathan Tobin, Partner – Brandon Capital
Plenty is written about the trends in dollars and modalities being invested in oncology by VCs. But equally important are the exits, and for early-stage investors M&A is especially important.... |
| 27.10.2025 | ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Clinical Studies of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections | Melbourne, Australia, 20 October 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antivirals that enhance the body’s natural viral defence mechanisms to minimise the impact of symptomatic viral respiratory infectio... |
| 03.10.2025 | George Medicines strengthens global commercialization strategy for GMRx2 with exclusive Biolab Farmacêutica licensing agreement in Brazil | Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, including two doses that are lower than those currently available in single pill combinations, designed to deliver the ... |
| 30.09.2025 | CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC | - |
| 22.09.2025 | ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK | Mohit Rawat appointed CEO, bringing deep biopharma leadership and a track record of driving innovations in drug discovery to commercial and transactional success; former CEO Robin Carr transitions to new CTO role
Expanded senior team across... |
| 16.09.2025 | CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development | Experienced executives, Clinton Musil, Sujata Rao, MD, Heike Krupka, PhD, and Andrea Goddard join CatalYm to broaden and accelerate clinical programs into late-stage development
Munich, Germany and San Francisco, USA, September 15, 2025 – C... |
| 08.09.2025 | NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND | - |
| 08.09.2025 | NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND |
Stevenage, UK, 8 September 2025 – NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B ... |
| 04.09.2025 | CUREator BioTech Incubator Grants $1.23M Top-Up Funding to High-Performing Participants | Melbourne, Australia, 4 September 2025 – CUREator, the Brandon BioCatalyst biotech Incubator, today announced $1.23 million in top-up funding for six high-performing participants from their Preclinical and Minimising Antimicrobial Resistanc... |
| 03.09.2025 | CatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial in Late-breaking Oral Presentation at ESMO | - |
| 20.08.2025 | Myricx Bio Awarded Cancer Research Horizons Start-Up Achievement Recognition Award for 2025 | London, UK, 11 July 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce that it has been awar... |
| 15.08.2025 | George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US | An innovative single-pill combination of three medicines, including two doses that are lower than those currently available in single-pill combinations, that can deliver the blood pressure-lowering benefits of a triple combination therapy e... |
| 24.07.2025 | Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close totalling over A$430 m | Melbourne, Australia Thursday, 24 July 2025 AEST: Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the final close of its sixth fund at A$439 million.
Joining existing investors Hesta, Host Plus, CS... |
| 10.06.2025 | Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management | Series D led by Lightstone Ventures, ClavystBio and WTT investment, supported by leading global syndicate of new and existing investors; Venture debt funding led by HSBC
Funds to advance ATX101 Phase 2b registration trial of post-surgical p... |
| 30.05.2025 | PolyActiva Secures $40M in Series C Financing to Advance PREZIA™ Platform Technology and Drive Innovation in Sustained Ocular Drug Delivery | MELBOURNE, AUSTRALIA – 30 May 2025– PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, today announced it secured AUD $40 million in Se... |
| 07.05.2025 | ENA Respiratory Appoints International Pharma Experts as Strategic Advisors to Support Development of INNA-051 Antiviral Host Defence Enhancer | Melbourne, Australia, 6 May 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of viral respiratory infections, announces today that it has appointed Kenny Simm... |
| 25.04.2025 | CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025 | Munich, Germany, April 25, 2025 – CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage antibody visugromab can improve the anti-tumor activity of antibody-drug conjugates (AD... |
| 17.04.2025 | FDA Approves WiSE® System, World’s First and Only Leadless Left Ventricular Endocardial Pacing (LVEP) Device for CRT | Every once in a while, a breakthrough doesn’t just advance medicine—it changes the conversation entirely.
SUNNYVALE, Calif., April 17, 2025 /PRNewswire/ — EBR Systems, Inc. (ASX: EBR) has received FDA approval of the WiSE® System, which mar... |
| 18.03.2025 | Vaxxas Secures New U.S. Patent For its Needle-Free Vaccination Manufacturing Technology | BRISBANE, Australia & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vaxxas, a clinical-stage biotechnology company, today announced it has secured a new patent from the United States patent office covering proprietary manufacturing technology for it... |
| 19.02.2025 | Allay Therapeutics Announces First Patients Dosed in Pivotal Phase 2b RegistrationTrial of ATX101 for Post-Surgical Pain Management After Knee Replacement Surgery | SAN JOSE, CA, February 18, 2024 (BUSINESSWIRE) – Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced that the ... |
| 18.02.2025 | Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery | BRISBANE, Australia & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vaxxas, a clinical-stage biotechnology company, today announced it has completed enrollment for its Phase I clinical trial of a vaccine against an avian influenza A (H7N9) virus wit... |
| 17.02.2025 | Axelia Oncology Announces a Clinical Supply Agreement with Regeneron for Trial Evaluating AXA-042 in Combination with Libtayo® (cemiplimab) | Combination of First-in-Class Systemic TLR2/6 Agonist and Anti-PD-1 Monoclonal Antibody to be Studied in Patients with Advanced Solid Tumours
MELBOURNE, AUSTRALIA – 14th Feb 2025, Axelia Oncology announced today that it has entered into a c... |
| 11.02.2025 | ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051 | Melbourne, Australia, 10 February 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it has received a U... |
| 10.02.2025 | AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing | Sydney, Australia – 3 February 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing. This ... |
| 03.02.2025 | AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing | Sydney, Australia – 3 February 2025 – AdvanCell, a clinical-stage radiopharmaceutical
company developing innovative cancer therapeutics, today announced the successful
completion of an oversubscribed US$112 million Series C financing. This ... |
| 29.01.2025 | ENA Respiratory Publishes Review of Development of Novel Intranasal Antiviral Host Defense Immune Enhancer INNA-051 in Antiviral Research | Publication comes as the prevalence of respiratory infections continues to rise worldwide
Melbourne, Australia, 28 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense immune enhancers to... |
| 22.01.2025 | ENA Respiratory Successfully Completes Phase Ib Dosing of Antiviral Host Defense Immune Enhancer INNA-051 Dry Powder Formulation in Older Adults and Advances Study in Young Adults | Melbourne, Australia, 22 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense immune enhancers to minimize the impact of viral respiratory infections in at-risk populations, announces tod... |
| 14.01.2025 | George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America | London, UK, 13 January 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing and supply agreement with Bausch Health... |
| 14.01.2025 | Vaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination | January xx, 2025 – BRISBANE, Australia & CAMBRIDGE, Mass. – Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, has been named a Concept Stage Winner of the... |
| 19.12.2024 | Certa Therapeutics Expands GPR68 Platform through Acquisition of OccuRx | Strengthened Pipeline Targets Multiple Fibrotic Diseases
Melbourne, Australia 19 December 2024: Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with fibrotic diseases, today announc... |
| 11.12.2024 | CatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD Conference | MUNICH– CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, visugromab, to mitigate cancer cachexia by neutralizing the G... |
| 06.12.2024 | Major Australian breakthrough could revolutionise hypertension treatment. | 27 November, 2024 MELBOURNE, Australia — In a significant international breakthrough for the more than one billion people suffering from hypertension, Australian-supported research recently published in three of the world’s leading medical ... |
| 21.11.2024 | Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers | Company’s First-in-Class, Oral, Highly Potent, and Selective Small Molecule Inhibitor of GPR65 Designed to Reverse Low pH-Induced Immunosuppression in the Acidic Tumour Microenvironment
MELBOURNE, AUSTRALIA and OXFORD, UK – November XX, 202... |
| 01.11.2024 | Aravax Completes Recruitment into Phase 2 Study of PVX108, a novel immunotherapy for the Treatment of Peanut Allergy | Melbourne, Australia – 28 October 2024, Aravax, a clinical-stage biotechnology company developing
next-generation immunotherapies designed to be safe, convenient, and precisely targeted, today
announces it has completed patient recruitment ... |
| 31.10.2024 | PolyActiva Showcases Promising Clinical Data Highlighting itsPolymer Technology’s Potential to Transform Glaucoma Care | Melbourne, Australia, 30 October 2024: PolyActiva, a clinical stage ophthalmology company, presented new clinical data from its Phase 2 clinical trial (LATA-CS102) for its novel glaucoma treatment technology, PA5108, at the Eyecelerator Con... |
| 18.10.2024 | Phase III trial results of novel triple combination pill for hypertension published in The Lancet | London, UK, 18 October 2024 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease treatment, today announced that The Lancet has published results from its pivota... |
| 16.09.2024 | Certa Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011) | Melbourne, Australia 16 September 2024: Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with fibrotic diseases, today announces that its lead candidate FT011 has been granted the In... |
| 10.09.2024 | Pheon Therapeutics Expands Board with Appointment of Dr. Enoch Kariuki | 10 September 2024
London UK, 10 September 2024 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the appointment of ac... |
| 06.09.2024 | NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND | Stevenage, UK, 5 September 2024 – NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a non-dilutive grant from Target ALS Foundation.
It is one of ... |
| 06.09.2024 | ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral | Melbourne, Australia, 5 September 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, h... |
| 27.08.2024 | ENA Respiratory Progresses Phase Ib Study of its Dry Powder Formulation of Intranasal Innate Immunomodulator INNA-051 | Melbourne, Australia, 27 August 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, ann... |
| 16.07.2024 | CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab | Munich, Germany, July 16, 2024 – CatalYm today announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion Growth Opportunitie... |
| 08.07.2024 | Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development | London, UK, 8 July 2024 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the closing of its series A financi... |
| 04.06.2024 | Brandon Capital Announces Sixth Fund with A$270 million (US$180 million) Initial Close to Drive Life Science Innovation | MELBOURNE, Australia – 4 June 2024 – Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the launch of its sixth fund, Brandon Capital Fund VI, with an initial close at A$270 million (US$180 million).
... |
| 21.05.2024 | Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline | London UK, 21 May 2024 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the completion of a $120m Series B financing ... |
| 13.05.2024 | Respirion offers hope for people living with cystic fibrosis | A promising new treatment pioneered in Western Australia for people with cystic fibrosis has commenced testing in a clinical trial in the United States and Australia.
Developed by researchers at Telethon Kids Institute and Perth Children’s ... |
| 07.05.2024 | Funding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential | CUREator by Brandon BioCatalyst has announced the deployment of $7.21 million in funding to support eight biotech companies across their Clinical and Preclinical streams thanks to the Federal Government’s Medical Research Future Fund’s Earl... |
| 30.04.2024 | ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator | Melbourne, Australia, 29 April 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, anno... |
| 30.04.2024 | Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic | Fundraising Includes New Strategic Investment by Bristol Myers Squibb along with Continued Support from Existing Investors including Canaan and Brandon Capital
Proceeds to be Used to Advance Lead Candidate, PTT-4256, into the Clinic and Exp... |
| 18.04.2024 | Fundraising Includes New Strategic Investment by Bristol Myers Squibb along with Continued Support from Existing Investors including Canaan and Brandon Capital | Proceeds to be Used to Advance Lead Candidate, PTT-4256, into the Clinic and Expand Leadership Team to Align with Pathios’ Transition into a Clinical-Stage Company
OXFORD, UK – April 18, 2024 – Pathios Therapeutics Limited (“Pathios”), a bi... |
| 02.04.2024 | Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases | —Azura to present 10 abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) and the Association for Research in Vision and Ophthalmology (ARVO), showcasing a breadth of data supporting the potential for a new therapeut... |
| 15.02.2024 | Brandon BioCatalyst, in partnership with ANDHealth, selected by Federal Government to deliver $50m Dementia and Cognitive Decline Incubator | Brandon BioCatalyst’s CUREator, in partnership with ANDHealth, is set to deliver a BioMedTech Incubator (BMTI) focused on developing research discoveries and medical innovations with commercial potential to address dementia and cognitive de... |
| 23.01.2024 | 23 Jan 2024: Aravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy | Aravax, a clinical stage biotechnology company developing the first rationally designed and precisely targeted immunotherapeutic for peanut allergy (PVX108), today announces it has closed its Series B funding round with a total of US$42.2m.... |
| 06.12.2023 | CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023 | Munich, Germany, December 6, 2023 – CatalYm announced that maturing Phase 2a results from its ongoing GDFATHER-2 trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 2) (NCT04725474) were presented today in an oral presentat... |
| 27.11.2023 | Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies | Scientists Uncover Central Role of N-Myristoylation in Senescence |
| 26.11.2023 | Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Ga... | CAMBRIDGE, Mass. & BRISBANE, Australia-Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has published positive results from a human clinical trial involving its potentially game-changing techn... |
| 16.11.2023 | Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma | Melbourne, Australia: 16 November 2023 – Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, announces the presentation of results of its Phase ... |
| 15.11.2023 | Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors | London, UK 15 November 2023 – Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), toda... |
| 02.11.2023 | PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery,biodegradable ocular implant in glaucoma patients. | Melbourne, 1st November 2023: PolyActiva is a Melbourne-based ophthalmology company developing a novel proprietary drug delivery platform. Today the company reported promising interim results from an ongoing Phase 2a clinical study for its ... |
| 19.10.2023 | Myricx Bio Wins Best Poster at World ADC | London, UK, 19 October 2023 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce that it has won the awar... |
| 09.10.2023 | - | Brandon Capital Joins AstronauTx’ £48 million ($61 million) Series A Financing to Create New Treatments for Alzheimer’s disease |
| 27.09.2023 | Recruitment completes for second Phase III hypertension trial investigating GMRx2 | George Medicines completes recruitment of second Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2
– More than 250 patients enrolled in placebo-controlled trial evaluating efficacy and safety of... |
| 27.09.2023 | Pathios Therapeutics Awarded Innovate UK Grant to Evaluate First-in-Class Immunotherapy Approach in Models of Malignant Brain Cancer | Company Collaborating with Researchers at the University of Nottingham on Optimization and Evaluation of Novel Small Molecule GPR65 Inhibitors in Preclinical Brain Tumor Models |
| 11.09.2023 | New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance | Melbourne, Australia and Milan, Italy, 11 September 2023 – ENA Respiratory, a clinical-stage pharmaceutical company, announced positive data from the Phase 2a flu challenge study of INNA-051, a first-in-class, broad-spectrum, innate immunom... |
| 05.09.2023 | Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer | BOSTON-Glyscend Therapeutics, a clinical-stage biopharmaceutical company that is reshaping the treatment of metabolic disease, including obesity and type 2 diabetes, with first-in-class oral polymer medicines that address unmet needs for pa... |
| 27.08.2023 | Dr. Yuri Maricich joins PKG Health as its Chief Medical & Scientific Officer | PKG Health is pleased to announce that Dr. Yuri Maricich has joined the leadership team as Chief Medical & Scientific Officer. |
| 23.08.2023 | VAXXAS AWARDED US$3.67 MILLION (AU$5.4 MILLION) FROM GLOBAL CHARITABLE FOUNDATION, WELLCOME, FOR HUMAN CLINICAL STUDY OF TYPHOID VACCINATION USING NEEDLE-FREE VACCINE PATCH | Cambridge, Mass., USA, and Brisbane, Queensland, Australia – August 23, 2023 – Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced that the global charitable foundation, Wellcome, has... |
| 15.08.2023 | CUREator+ delivers $50m funding boost to commercially focused BioMedTech startups | Expressions of Interest for CUREator+, a newly created $50 million program by Brandon BioCatalyst and ANDHealth, are now open. |
| 03.08.2023 | Cicada Innovations to launch new health-focused hub in Westmead Health Precinct alongside Brandon BioCatalyst | Australia’s flagship deep tech incubator Cicada Innovations is expanding with the opening of a health-focused incubator at one of Australia’s largest health and biomedical research precincts, the Westmead Health and Innovation District, and... |
| 18.07.2023 | State Government Backs OncoRes Medical with Funding to Manufacture Digital Cancer ImagingDevice in WA | Perth, 18/07/2023 – OncoRes Medical, a Perth-based medical device company, has secured $3M grant funding from the Cook Government’s Department of Jobs, Tourism, Science, and Innovation, further bolstering their successful financial year.... |
| 06.06.2023 | Vaxxas Appoints Dr. Rochelle Chaiken as Chief Medical Officer | Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform technology, today announced the appointment of Dr. Rochelle Chaiken, as Chief Medical Officer. Dr. Chaiken joins Vaxxas following a 23-year career a... |
| 06.06.2023 | Vaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine | Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ p... |
| 02.06.2023 | Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity | BOSTON–(BUSINESS WIRE)–Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered first-in-class gut-targeted polymer therapies, today announced clinical progress with its lead candidate... |
| 02.06.2023 | Aravax doses first patient in Phase 2 peanut allergy clinical trials | The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Aravax, which is developing the novel therapy PVX108 for the safe and convenient treatment of peanut allergy. The study is being conducted unde... |
| 24.05.2023 | Nineteen groundbreaking biotech projects selected for national incubator | CUREator, Australia’s national biotech incubator, today announces its second round of funding, awarding $12 million to 19 projects targeting global health challenges including advances in treatment for lupus, motor neurone disease, brain an... |
| 22.05.2023 | EBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation | Melbourne, 22 May 2023 – EBR Systems, Inc. (ASX: EBR), the medical device company developing wireless cardiac pacing systems, has met its primary safety and efficacy endpoints in its pivotal SOLVE-CRT trial of the WiSE® Cardiac Resynchroniz... |
| 22.05.2023 | EBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation | EBR Systems, Inc. (ASX: EBR), the medical device company developing wireless cardiac pacing systems, has met its primary safety and efficacy endpoints in its pivotal SOLVE-CRT trial of the WiSE® Cardiac Resynchronization Therapy (CRT) Syste... |
| 03.05.2023 | Healthcare Veteran, Zach Henderson to lead Global Kinetics as CEO | Charlotte, US & Melbourne, Australia – May 3, 2023, Global Kinetics, the global leader in digital health solutions for neurological conditions, today announced the appointment of Zach Henderson as its new Chief Executive Officer. Zach w... |
| 21.03.2023 | Brandon BioCatalyst, in partnership with ANDHealth, selected by the Federal Government to deliver $50m BioMedTech Incubator Program | Federal investment creates a combined funding capability of $115m across programs managed by Brandon BioCatalyst & ANDHealth. |
| 10.03.2023 | Aravax initiates Phase 2 peanut allergy clinical trials in Australia | Aravax, a clinical stage biotechnology company developing next generation immunotherapies which are safe, convenient, and precisely targeted, today announces it has initiated the first clinical trial sites in Australia for AVX-201 in Austra... |
| 09.03.2023 | Tech entrepreneur amongst stellar cohort in latest Women in Leadership Development (WILD) Program, which is expanding with new Federal investment | One of Australia’s most promising tech entrepreneurs joins a stellar cohort partaking in this year’s Women in Leadership Development (WILD) Program, which starts in Melbourne this week. |
| 14.02.2023 | Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study | ENA Respiratory, a clinical-stage pharmaceutical company, announced that INNA-051, a first-in-class, broad-spectrum, innate immunomodulator in development for the prophylaxis of respiratory viral infections, was found to significantly impac... |
| 10.02.2023 | Vaxxas initiates Phase I study for needle-free seasonal influenza vaccine delivered using High-Density Microarray Patch (HD-MAP) | Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate deli... |
| 06.02.2023 | Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients | Certa Therapeutics (Certa) today announces ground-breaking clinical trial data for FT011, its novel therapy for the treatment of serious inflammatory and fibrotic diseases. |
| 19.01.2023 | Coming in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access | CEPI, the Coalition for Epidemic Preparedness Innovations, and Vaxxas , a clinical-stage biotechnology company commercializing a novel vaccination platform, have signed a partnership agreement to advance the development of Vaxxas’ needle-fr... |
| 10.01.2023 | ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051 | Clinical-stage pharmaceutical company ENA Respiratory has been awarded a $4.38 million USD agreement from the U.S. Department of Defense (DoD) to support ongoing research and development of INNA-051, a clinical stage first-in-class broadspe... |
| 20.12.2022 | Billionaires Andrew and Nicola Forrest take aim at peanut allergy | Billionaires Andrew and Nicola Forrest are taking aim at peanut allergy with their new healthcare venture, backing a small biotech looking to develop the first safe, convenient, and targeted treatment for the common allergen. |
| 20.12.2022 | Aravax commences Phase 2 development for peanut allergy therapy with $20m commitment to Series B round from Brandon Capital and Tenmile | Aravax, a clinical stage biotechnology company developing the first safe, convenient, and precisely targeted immunotherapeutic for peanut allergy (PVX108), today announces it has commenced its series B funding round with an investment of US... |
| 06.12.2022 | Vaxxas Raises US$23 million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate | Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced it has completed a financing round which raised US$23 million (A$34 million) in new funds. This investment round was led by existin... |
| 06.12.2022 | Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement | Entact Bio, the company pioneering the development of precision medicines that enhance the function of key proteins, today announced it has raised $81 million in Series A financing to advance its proprietary Encompass™ platform for developi... |
| 22.11.2022 | CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors | CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Nov... |
| 17.11.2022 | Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction | – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced positive 3-month efficacy and safety results from its Phase 2b s... |
| 11.11.2022 | QUE Oncology’s non-hormonal therapy reduces hot flushes and night sweats in women with breast cancer, published in The Lancet | QUE Oncology announces the results of its Phase II trial of Q-122, a novel non-hormonal oral therapy for the treatment of vasomotor symptoms (commonly known as hot flashes/flushes and night sweats) in women taking endocrine therapy for brea... |
| 09.11.2022 | First Aussies to get needle-free COVID-19 vaccine patch | - |
| 09.11.2022 | Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP) | Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietar... |
| 09.11.2022 | Brandon Capital Invests in Neuroscience Company NRG Therapeutics | Brandon Capital, Australasia’s leading life science venture capital firm, is pleased to announce its investment into neuroscience company NRG Therapeutics as part of its £16m (AUD$29m) series A financing. |
| 04.11.2022 | Certa Therapeutics’ investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases | Certa Therapeutics’ investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases |
